多替阿巴拉米片阻断效果好吗
AIDS is a chronic infectious disease. For patients, medication compliance is very important. (Suimeikai) is China's first complete single-piece three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance.
Is the blockade effect of Dote Abalami Tablets?
Dolutea Balami Tablets (Simeika) is a drug containing three active ingredients. Existing research shows that 93% of HIV-infected patients became negative for viral load one year (48 weeks) after treatment with Simeike.
Dolutegra abalamide tablets (Simeika) cannot be used for individuals who carry the HLA-B*5701 gene. Patients carrying this gene have a high risk of severe hypersensitivity reactions (type I allergic reactions) when using Simeika. Therefore, before taking Doptabalamid Tablets (Suimeike), you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene.
Patients treated with Dolutegra (Trimax) should be advised that patients with pre-existing hepatic dysfunction, including patients with chronic active hepatitis, may develop hepatic dysfunction with increased frequency during combined antiretroviral therapy and should be monitored according to standard protocols. If there is evidence of worsening liver disease in these patients, consideration should be given to withholding or discontinuing doptabalamid therapy.
For the elderly population, there are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using dolutea (Simeike) in this age group.
The above is the introduction about (Sui Mei Kai). If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.
Recommended related hot articles: /newsDetail/85402.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)